Key result
The SYT-SSX fusion type (SYT-SSX1 vs SYT-SSX2) was not a significant prognostic factor for 5-year overall survival (84.4% vs 74.9%, p=0.244) in patients with localized synovial sarcoma.
Why the study?
Does SYT-SSX fusion type impact overall survival and metastasis-free survival in patients with synovial sarcoma?
Population
108 SYT-SSX fusion transcript-positive patients with synovial sarcoma, treated in 11 tertiary referral…
Comparison
SYT-SSX1 fusion type vs SYT-SSX2 fusion type
Design
Cohort
Follow-up
median 54 months
Authors
Loading...
SYT-SSX fusion type should not guide prognosis in localized synovial sarcoma; leaves open tumor size as dominant factor for validation.
Cohort (n=108)
Yes
Does SYT-SSX fusion type impact overall survival and metastasis-free survival in patients with synovial sarcoma?
Absolute Event Rate: 84.4% vs 74.9%
p-value: p=0.244
The SYT-SSX fusion type is not a significant independent prognostic factor for overall or metastasis-free survival in patients with localized synovial sarcoma, whereas tumor size is.
Takenaka et al. (2008) conducted a cohort in Synovial sarcoma (n=108). SYT-SSX1 fusion type vs. SYT-SSX2 fusion type was evaluated on 5-year overall survival in localized disease (p=0.244). The SYT-SSX fusion type (SYT-SSX1 vs SYT-SSX2) was not a significant prognostic factor for 5-year overall survival (84.4% vs 74.9%, p=0.244) in patients with localized synovial sarcoma.